Immutep

Clinical-stage immuno-oncology company built around the LAG-3 immune checkpoint. Lead asset eftilagimod alpha (efti) is a soluble LAG-3 fusion protein in Phase 3 TACTI-004 (KEYNOTE-F91) for first-line non-small cell lung cancer in combination with pembrolizumab and chemotherapy. Pipeline also includes IMP761, a first-in-class agonist LAG-3 antibody for autoimmune disease.